Antares Pharma, Inc. (ATRS)
$
5.59
+0.01 (0.18%)
Key metrics
Financial statements
Free cash flow per share
0.1763
Market cap
0
Price to sales ratio
0
Debt to equity
0.1363
Current ratio
2.7441
Income quality
0.7911
Average inventory
14.9 Million
ROE
0.3140
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey. As of May 23, 2022, Antares Pharma, Inc. operates as a subsidiary of Halozyme Therapeutics, Inc.
News
zacks.com
Antares Pharma (ATRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
invezz.com
Antares Pharma Inc shares (NASDAQ: ATRS) are up 45% on Wednesday after Halozyme Therapeutics said it will buy the New Jersey-headquartered company for $960 million in cash. Details of the agreement The deal translates to $5.60 per share for Antares Pharma shareholders that translates to a close to 50% premium on where the stock closed […] The post Antares Pharma Inc shares up 45% on Wednesday: how come?
benzinga.com
Antares Pharma Inc (NASDAQ: ATRS) shares are trading higher Wednesday after the company announced it will be acquired by Halozyme Therapeutics Inc (NASDAQ: HALO) for $5.60 per share in cash, valuing Antares at approximately $960 million. The transaction was unanimously approved.
investorplace.com
Antares Pharma (ATRS) stock is rocketing higher on Wednesday after the company reached an acquisition agreement with Halozyme (HALO). The post Why Is Antares Pharma (ATRS) Stock Up Today?
pennystocks.com
Here's what you need to know about trading penny stocks on April 13th The post Best Penny Stocks to Buy? 3 to Watch as ATRS Stock Explodes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
fool.com
The drug delivery specialist has reportedly agreed to a merger with Halozyme.
marketwatch.com
Shares of Antares Pharma Inc. ATRS, -0.27% rocketed 46.3% in premarket trading Wednesday toward a two-decade high, after the specialty pharmaceutical company agreed to be acquired by Halozyme Therapeutics Inc. HALO, +0.58% in a cash deal valued at $960 million. Halozyme's stock was still inactive ahead of the open.
benzinga.com
Antares Pharma Inc (NASDAQ: ATRS) has nabbed another FDA approval, and the Company's second involving testosterone. The Company announced FDA approval for Tlando (testosterone undecanoate), an oral treatment for testosterone replacement therapy indicated for deficiency or absence of.
seekingalpha.com
Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q4 2021 Results - Earnings Call Transcript
zacks.com
Antares Pharma (ATRS) delivered earnings and revenue surprises of 100% and 5.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
See all news
